Trial Profile
A randomized double blind study to evaluate the lipid modifying, anti-inflammatory, antioxidant efficacy and tolerability of combination of atorvastatin and ezetimibe versus atorvastatin in patients with dyslipidemia.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Atorvastatin/ezetimibe (Primary) ; Atorvastatin
- Indications Dyslipidaemias
- Focus Therapeutic Use
- 28 Feb 2011 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.
- 16 Feb 2010 New trial record